Last week, Newtown-based Traws Pharma reported its full-year 2025 financial results and provided updates on its influenza and COVID drug programs.
The company, which develops novel therapies to target critical threats to human health from respiratory viral diseases, also reported the completion of a private investment in public equity financing of up to $60 million in gross proceeds.
The financing, combined with current cash and cash equivalents of approximately $3.8 million, will fund operations into the first quarter of 2027. This will include a planned Phase 2a human challenge trial for TXM as an influenza prophylactic.
“Traws has made substantial progress over the last year, towards our goal of advancing our potential best-in-class influenza program as a prophylactic agent,” said Dr. Iain Dukes, Chief Executive Officer of Traws Pharma.
Traws also reported that final analysis is already underway for the 90-patient Phase 2a study of Ratutrelvir, which showed safety and proof-of-concept efficacy as a potential treatment for acute COVID infection.
The company posted $2.8 million in revenue for the year ended December 31, 2025, compared with $0.2 million a year earlier. Net income reached $9.2 million, translating to $0.83 per basic share and $0.82 per diluted share.
Learn more about the Newtown-based pharmaceutical company and details on their 2025 financial report at Traws Pharma.
_______
